Internet Archive Scholar

18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model

N. Aide, K. Kinross, C. Cullinane, P. Roselt, K. Waldeck, O. Neels, D. Dorow, G. McArthur, R. J. Hicks
2010 Journal of Nuclear Medicine  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (3.7 MB)
https://web.archive.org/web/20170809123806/http://www.snm.org/docs/pr/100110/Cisplatin%20Resistant%20Ovarian%20Tumor%20Model.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL. The file type is application/pdf.

preclinical or clinical trials evaluating treatment of cisplatinresistant ovarian tumors by mTOR inhibitors.
doi:10.2967/jnumed.109.073288 pmid:20847160 fatcat:ss5o4rve3veezbjsbcg2jgbmve
Citation

N. Aide, K. Kinross, C. Cullinane, P. Roselt, K. Waldeck, O. Neels, D. Dorow, G. McArthur, R. J. Hicks. "18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model." Journal of Nuclear Medicine 51.10 (2010) 1559-1564